114 results about "Anti her2" patented technology

Methods for treating a subject with a cancer that is characterized by overexpression of HER2 receptor protein using a combination of interleukin-2 (IL-2) or variant thereof and at least one anti-HER2 antibody or fragment thereof are provided. These anti-tumor agents are administered as two separate pharmaceutical compositions, one containing IL-2 (or variant thereof), the other containing at least one anti-HER2 antibody (or fragment thereof), according to a dosing regimen. Administering of these two agents together potentiates the effectiveness of the anti-HER2 antibody alone, resulting in a positive therapeutic response that is improved with respect to that observed with this anti-tumor agent.

The invention belongs to the biochemistry technical field, concretely relates to a method for purifying anti-HER2 or/and anti-HER3 antibody proteins. The method of the invention comprises the following the steps: clarifying a broth, carrying out affinity chromatography, carrying out inactivation on virus by acidic pH value, carrying out cation exchange chromatography, carrying out anion exchange chromatography; and filtering virus; wherein, the step of virus inactivation by acidic pH value and the step of virus filtration can be inserted at any position of the step after the affinity chromatography. The method of the invention comprises the following advantages that: 1) the chromatography step can be reduced to three steps, thereby the production efficiency can be enhanced and the production cost can be minimized. 2) the step of virus filtration is added, thereby the security can be raised.

Therapeutic protein fusions comprising anti-HER2 antibody and MicB sequences are described along with methods for their production and use

The invention provides miRNA signatures and methods of making and using thereof. MiRNA signatures determine the responsiveness of HER2 expressing breast tumors to anti-HER2 treatment, such as the targeted drug therapy trastuzumab.

Relating to the technical field of pharmaceutical preparations, the invention provides an antibody composition preparation composed of Trastuzumab and Pertuzumab. The antibody composition preparation has better tumor treatment activity. Compared with the independent treatment of Trastuzumab and Pertuzumab, the composition preparation shows a synergistic effect of the two antibodies, and can reach a tumor control rate of 92.43%. And the preparation provided in the invention has better stability, thus being in favor of long-term preservation of the antibody composition preparation. The antibody composition preparation provided in the invention is applicable to preparation of drugs treating diseases or symptoms suited to anti-HER2 antibody therapy. During application, the antibody composition preparation disclosed in the invention is used with a chemotherapeutic agent jointly or sequentially.

The invention discloses an HER2-resistant humanized antibody and a relevant tumor-resistant composition thereof. The HER2-resistant humanized antibody in the tumor resistant composition provided by the invention is an HER2-resistant humanized antibody M1 containing a humanized heavy chain variable region M1-VH and a humanized light chain variable region M1-VL which both consist of a determinant complementary region and a framework region, the determinant complementary regions of the M1-VH and the M1-VL both consist of CDR1, CDR2 and CDR3; the amino acid sequences of the CDR1, the CDR2 and the CDR3 of the M1-VH are respectively shown as the 26th to 35th, the 50th to 66th, and the 99th to 109th of the SEQID No.1; the amino acid sequences of the CDR1, the CDR2 and the CDR3 of the M1-VL are respectively shown as the 24th to 40th, the 56th to 62th, and the 95th to 103th of the SEQID No.2.

The invention discloses a humanized anti-HER2 antibody preparation, which contains humanized anti-HER2 antibody, protective agent, buffering agent, surfactant and isotonic regulator. The invention has the advantages of stability and low price.

A humanized monoclonal antibody of human endophloeodal growth factor receptor 2 protein is prepared from enternal segment of HER2/neucell through such steps as culturing the B cells of the person sensitive to HER2; fusing the said B cells with human osteoma cells (karpas 707 H); screening the external segment monoclonal anti body against HER2 cell; and amplification of the said monoclonal antibody. It features that antigen epitope is the external segment polypeptide of HER2/neu cell for specifically binding the external segment of HER2/neu cell, and the all gene sequences for syntehsis come from human B lymph cells and human osteoma cells.

The present invention relates to humanized bispecific anti-HER2 antibodies that comprise one antigen binding site containing variable regions of heavy and light chain of trastuzumab, and another antigen binding site containing variable regions of heavy and light chain of pertuzumab. The bispecific anti-HER2 antibodies is effective for treating cancer, such as breast cancer, gastric cancer, or ovarian cancer. Preferred bispecific anti-HER antibodies of the present invention are afucosylated antibodies. The present invention also relates to Chinese Hamster ovary (CHO) mutant cell line that has a dysfunctional Slc35C1 gene, which is the only dysfunctional gene in the mutant that affects glycan regulation.

The present invention relates to novel therapeutic antibodies directed against HER2 (ErbB2), as well as recombinant polyclonal anti-HER2 antibody compositions, and use of the antibodies and antibody composition for treatment of cancers. The antibody composition comprises at least three recombinant antibodies that bind distinct epitopes of HER2. Two of the antibodies bind to HER2 on the surface of a cell such that they generate a cross-linked antibody-receptor lattice on the cell surface and thereby result in HER2 receptor internalization. The third antibody in the composition binds HER2 such that it blocks heterodimerization between HER2 and HER3.

The invention provides a fully human anti-HER2 monoclonal antibody, which has an amino acid sequence of heavy chain variable region as shown in SEQ ID NO: 6 and an amino acid sequence of light chain variable region as shown in SEQ ID NO: 8. The invention also discloses the nucleotide sequence encoding the antibody, the expression vector and the host cell comprising the nucleotide sequence, and the use of the antibody for manufacturing the medicament for the treatment of tumor.

The invention discloses a chimeric antigen receptor T (CAR-T) cell as well as a preparation method and application thereof, wherein the CAR of the CAR-T cell comprises a cell membrane exoantigen binding region, a hinge region and an intracellular signal transduction region; the cell membrane exoantigen binding region is chA21scFv for combining with HER2 protein; and the intracellular signal transduction region is CD28-X-ITAM, wherein the X is ICOS, CD137, CD134, CD80 or CD86 costimulatory molecule. The chA21scFv of the CAR-T cell can express anti-HER2 monoclonal antibody, and the HER2 protein is as a target to directly recognize and combine with HER2 protein highly expressed on the surfaces of tumor cells, so that T cells are activated, and cell factors for killing the tumor cells expressing the HER2 protein are secreted.

Combinations of the antibody-drug conjugate trastuzumab-MCC-DM1 and chemotherapeutic agents, including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting tumor cell growth, and for treating disorders such as cancer mediated by HER2 and KDR (VEGFR receptor 1). Methods of using such combinations for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

The invention relates to the biotechnical field, and especially relates to a bispecific antibody. The bispecific antibody comprises a first antibody segment and a second antibody segment, the first antibody segment is an antitumor antigen-antibody segment, and the second antibody segment is an anti-human CD3 molecule antibody segment. A bispecific antibody principle is used to construct the Her2 tumor antigen and T cell specific bispecific antibody, and adoptively transferred T cells are used to carry and continuously express the antibody protein in vivo, so the bispecific antibody has an in vivo killing effect, generates enough T effect effects, and optimizes the effect performance efficiency.

An active fragment for the mutual action between HER2/neu and Herstation is the polypeptide with the amino acid residue sequence shown by SEQ ID No.1 or the polypeptide whose amino acid residue sequence has one or more substituted or lost, or added residues. It is also a sensitive site, where HER2/neu molecule can be effectively suppressed. It can play its role in preparing the HER2/neu antagonistic medicines.

The invention provides a novel bifunctional antibody conjugate, a preparation method and application thereof. The bifunctional antibody conjugate provided by the invention includes the structure of: a first antibody specifically directed at immune cells and a second antibody specifically directed at tumor markers, with the two antibodies coupled together through a coupling arm. The bifunctional antibody conjugate can significantly improve the tumor-killing activity after combination with an immune cell (like CIK). The invention also provides application of the novel bifunctional antibody conjugate in treatment of tumors and other diseases. The invention also provides an anti-HER2 positive cancer bispecific antibody and a preparation process. According to the invention, the bispecific antibody with high coupling rate and high activity can be simply and quickly produced, and the CIK tumor-killing activity can be improved by 2-6 times.

The invention discloses an anti-Her2/PD-1 bispecific antibody and a preparation method thereof, and belongs to the field of biotechnology. The anti-Her2/PD-1 bispecific antibody can bind to Her2 and bind to PD-1, and can effectively enhance immune response by blocking a Her2 and/or PD-1 signaling pathway, so that the anti-Her2/PD-1 bispecific antibody is possible to have a good effect of enhancingthe anti-tumor immune response.

The invention provides an anti-HER2 polyclonal antibody as well as a preparation method and application thereof, wherein the anti-HER2 polyclonal antibody is applied in preparation of an immune detection tool for detecting HER2 protein. The anti-HER2 polyclonal antibody is applied in preparation of a kit used for diagnosing malignancy generated by excessive HER2 expression. The anti-HER2 polyclonal antibody provided by the invention is used for providing a high-specificity, high-sensitivity and high-quality antibody for HER2 protein antigen detection.

The invention provides a fucose-removed anti-HER2 antibody which is produced by cells with the FUT8 gene knocked out. The amino acid sequence of the fucose-removed anti-HER2 antibody is shown as SEQ ID NO: 1, and the nucleotide sequence is shown as SEQ ID NO: 2. Furthermore, the antibody comprises a CH2 structural domain; the amount of fucose in the CH2 structural domain is zero. The invention further provides a medicine with the fucose-removed anti-HER2 antibody serving as an active ingredient, and a reagent, a composition or a kit with the fucose-removed anti-HER2 antibody serving as an active ingredient. Compared with a fucose-containing anti-HER2 antibody, the antibody disclosed by the invention is higher in activity, and shows good tumor inhibition activity in both expression and low expression of herceptin-resistant HER2.